Fennec Pharmaceuticals Inc. (NASDAQ: FENC) on Tuesday shared topline results from the investigator-initiated Phase 2/3 STS-J01 trial of Pedmark (sodium thiosulfate injection) to reduce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback